-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Viatris delivered solid Q1 2026 results with revenues of $3.517B (+8% Y/Y), $150M above consensus, and adjusted EPS of $0.59 (+18% Y/Y), beating consensus by $0.09. Adjusted EBITDA grew 14% Y/Y to $1.049B, demonstrating meaningful operating leverage from the completed strategic review. The brands portfolio showed strong momentum with $2.3B in net sales (+10% Y/Y), driven by exceptional Greater China performance (+22% Y/Y) and continued Emerging Markets strength, while generics stabilized at $1.177B (+5% Y/Y). Management reaffirmed all 2026 guidance ranges, including total revenues of $14.45B-$14.95B and adjusted EPS of $2.33-$2.47, despite incorporating the February Nashik facility fire impact. New product development remained on track with $71M in Q1 revenues toward the $450M-$550M full-year target. In our view, the strategic review has been successful so far to drive operational improvements in Q1, while positioning Viatris for healthy growth.